SENSEX NIFTY
Kopran > Company History > Pharmaceuticals > Company History of Kopran - BSE: 524280, NSE: KOPRAN
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Kopran
Kopran
BSE: 524280|NSE: KOPRAN|ISIN: INE082A01010|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Sep 16, 16:05
63.75
-6.2 (-8.86%)
VOLUME 1,007,975
LIVE
NSE
Sep 16, 16:05
63.90
-6.1 (-8.71%)
VOLUME 2,249,410
Company History - Kopran
YEAR                                                         EVENTS
 1958 - The Company was incorporated on 26th April, as a private
 limited
        company under the name Kopran Chemical Company Pvt. Ltd. by
 Shri
        Ramanlal V Shah, Sevantilal A Shah, Chimanlal G Sheth and
        Jivanalal M Shah in 1972, the Company's management was
 acquired 
        by Chemo Pharma Laboratories Ltd and the Company's products
 were
        marketed by them.
 
 1984 - The Company was converted into a public limited company on
 24th
        August.
 
 1985 - In a special purpose antibiotic bulk drug Cephlaxin
 Monohydrate
        and an anti-TB formulation Rifampicin were launched in
 technical
        co-operation with Yuhan Corporation, South Korea to Support
 its
        expanding product base the Company integrated backwards into
        manufacture of 6APA a raw material required for bulk drug
        production.
 
 1990 - The Company changed its name to Kopran Limited on 22nd
 August.
 
      - The Company is engaged in the manufacture of pharmaceuticals
 and
        bulk drugs. Originally the Company manufactured medical
        formulations with production of bulk drugs and drug
 intermediates
        being introduced in 1983.
 
      - The Company has built up its strengths in the production of a
        wide range of semi-synthetic Penicillins such as Ampicillin
        trihydrate, Cloxacillin Sodium and Amoxycillin Trihydrate in
        addition to producing several other bulk drugs and
 formulations
        prominent amongst which are VENT, ATEN, TINI 300, BREN 400
 and
        Dilgina.
 
 1992 - The Company was amongst the first to launch a new concept in
 the
        treatment of ulcers-Omeprazole under the brand name of LOKIT.
 
      - The company has been one of the promoters of Pharmacuetical
        Business Group (India) Ltd. a company which has been promoted
        along with M/s Lyka Laboratories Ltd., Themis Chemicals Ltd.,
        Cadila Laboratories Ltd. and Anant & Co. to acquire the
        management of Gujarat Themis Biosyn Ltd.- a company
 manufacturing
        basic drugs from fermentation.
 
      - In November, the company issued for public subscription
 16,00,000 
        equity shares of Rs 10/- each at a premium of Rs 80/- per
 share
        aggregating Rs 1440 lakhs and subsequent to that the capital
 was
        increased to Rs 8,00,00,000.
 
 1993 - The company has once again won the second award for export 
        performance for the year 1991-92 from CHEMEXCIL.
 
 1994 - The Company promoted two subsidiaries, viz., Kopran
 International
        in United Kingdom and Kopran (H.K.) based in HongKong.
 
      - The Company have been rewarded by two esteemed awards
 received
        during 1993 viz., Indian Drug Manufacturers Association's
 QUALITY
        EXCELLENCE AWARD 1993 and the EUROPE QUALITY AWARD - 1993.
 
 1995 - The Company issued Bonus Equity Shares in the ratio of 1:2,
        thereby increasing the Capital by Rs. 4.00 crores.
 
 1996 - The Company has received the TRISHUL Award under the Large
 Scale
        Manufacturer category from CHEMEXCIL and Certificate of Merit
        from the Ministry of Commerce.
 
      - The Company has launched various new products like TRASIC
        (Tramadol - a potent analgesic). SOLOFLOX (Lomefloxacin - a
 new
        anti-bacterial), ZIMAT (Cetirizine - an anti-allergic) apart
 from
        various brand extensions and newer combinations.
 
 1997 - The company launched various new products like AZ-1 Caps. 
 Klodip
        Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps,
 Amyn
        Dry Syrup.
 
      - The company entered into a joint venture with M/s. Industrial
        Promotion Services Ltd. (a subsidiary of the Aga Khan Fund
 for
        Economic Development) to take over a running unit viz.
 Kampala
        Pharmaceutical Industries (1996) Ltd, in Uganda.
 
      - Kopran Limited has won for the fourth time in a row, the IDMA
        Award for Quality Excellence
 
      - Kopran Ltd, the second largest manufacturer of semi-synthetic
        penicillins in the world.
 
      - Kopran Ltd has entered into a memorandum of understanding
 (MoU)
        with Pharmacare Ltd to set up a 50:50 joint venture project
 for
        the manufacture of penicillin-based products in South Africa.
 
 1998 - Kopran Drugs Ltd and Synpac Pharmaceuticals Ltd (UK) have
        entered into a strategic alliance whereby Synpac will be a
        primary supplier of penicillin G to Kopran Drugs Ltd and
 shall
        buy back Penicillin based products from Kopran Drugs for the
        international market.
 
      - Kopran Ltd has set up a dedicated marketing division for the
        same, under Kresp. 
 
 1999 - Kopran Drugs Ltd, set up under a strategic alliance with the
        UK-based Synpac Pharmaceuticals.
 
      - Kopran is re-examining its diagnostics tie-up with US-based
        Chiron Diagnostics following the latter's proposed global
        takeover by Bayer Diagnostics.
 
      - Kopran Ltd is setting up a pharmaceutical company in Dubai in
        association with Dubai Investments PJSC (Public Joint Stock
        Company).
 
      - Kopran has a state-of-the-art formulations plant at Sarvoli,
        which is expected to stand the company in good stead for
        targeting export markets.
 
      - The UK-based Synpac Pharmaceuticals, a leading penicillin
        manufacturer, is set to become a joint venture partner in
        Kopran Drugs, the antibiotics division which was hived off
        from the fast growing Kopran Ltd.
 
 2000 - Kopran Pharmaceuticals, associated with the popular Smyle
        brand, has introduced the `American Dreams' range of fine
        perfumes in India, under a distribution arrangement with a
        US-based company.
 
      - Kopran Pharmaceuticals to launch another umbrella brand
        along the lines of its flagship brand Smyle.
 
      - The Company has decided to issue equity shares to members,
        employees, NRIs, OCBs, FIIs, MFs, IFIs, companies and/or other
 
        entity/entities and to such other persons by way of public
 issue,
        rights issue preferential allotment or on private placement
        basis.
 
      - Kopran Pharmaceuticals has launched a range of digestive
 tablets
        branded Yum Tum.
 
      - KResp, a division of Kopran Ltd., has launched a new aerosol
        holding device, which is smaller in size called `Vent-Mate'.
 
       - Pharmaceuticals company Kopran Ltd has tied up with E Merck
 India for marketing
          Atorvastain, a new product in the anti-cholesterol segment,
 in India.
 
         - Kopran Ltd have fixed the swap ratio for the merger of
 group company Kopran 
           Pharmaceuticals with it at 17:1.
 
         - Kopran Ltd is to issue 40 lakh equity shares at Rs 150 per
 share to shareholders of
           group company Kopran Pharmaceuticals Ltd, as part of the
 merger.
 
 2001 - The Company has tied up with E Merck Ltd for a co-marketing
 arrangement for a new
              antiinflammatory oranalgestic drug Rofecoxib, for the
 Indian market.
 
            - Kopran Ltd. is launching Dr Smyle Prickly Heat Powder,
 in a pack of 150g.
 
            -  Kopran Ltd, the Rs 900 crore pharma major, has sold the
 marketing rights for its anti-hypertensive drug                       
     'Aten' to Zydus Cadila for a consideration of Rs 75 crore.
 
 2002-Kopran Ltd has informed BSE that Mr Humayun Dhanrajgir has
 resigned from Directorship.
 
 2003
 
 -Receives approval from the patent office of the US for its new
 chemical entity (NCE), KNC-6
 
 -Received an approval for restructuring its high cost debts from the
 Corporate Debt Restructuring (CDR) Cell. The key highlights of this
 restructuring is as follows:
 
 1. The rates of interest both on long term debts and the working
 capital borrowing would come down from the current 13.50% to 9%
 leading to significant reduction of the interest cost.
 
 2. The repayments of long-term debts have been rescheduled to be paid
 by 2009.
 
 3. Release of additional working capital to meet requirements of the
 planned growth in business.
 
 - HSBC Financial Services has acquired a 6.06 per cent stake in
 Kopran Pharmaceuticals, taking its holding in the Mumbai-based
 pharmaceutical company to 10.01 per cent.
 
 -Kopran receives approval from EDQM for its API facility at Mahad
 
 2004
 
 Kopran Ltd has informed that The Stock Exchange Ahmedabad (ASE) vide
 letter dated April 08, 2004 have delisted the shares of the Company
 w.e.f. April 08, 2004.
 
 -Merrill Lynch Capital Markets Espana SA SV, has acquired an 8.49 per
 cent stake in drug maker Kopran through the open market
 
 -Kopran Ltd has informed that at the meeting of the BoD of the
 company held on July 31, 2004, Board has recorded and accepted the
 resignation of Mr. Tapan Ray, Managing Director of the company with
 effect from October 31, 2004
 
 2005
 
 - The Company has appointed Mr.H.P.Vyas as Company Secretary.
 
 - The Company has entered into a Strategic Alliance with Merck
 Specialities Pvt Ltd.
 
 2006
 
 - The company has signed a distribution pact with Mumbai-based Manish
 Pharma for its complete range of over the counter (OTC) products.
 
 2011
 
 - The company has appointed Mr. Abhinav Mathur as a Company Secretary
 & Compliance Officer.
 
Source : Dion Global Solutions Limited
Quick Links for Kopran
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.